We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Toxicity Secondary to Intravenously Administered Chloroform in Humans

Richard M. Timms, MD; Kenneth M. Moser, MD
Arch Intern Med. 1975;135(12):1601-1603. doi:10.1001/archinte.1975.00330120079011.
Text Size: A A A
Published online


The association of pulmonary disease and chloroform (CHCL3) injection has not been recorded previously in humans as far as we know. However, other halogenated, volatile hydrocarbons such as carbon tetrachloride and trichlorethane are known to induce pulmonary injury. Carbon tetrachloride (CHCL4) causes pulmonary edema and hemorrhage when given intravenously to dogs.1 Oral doses of carbon tetrachloride were recently shown to cause diffuse pulmonary damage in rats at sublethal dosage levels.2 There is evidence that inhaling high concentrations of trichloroethane (CH3CCL3) may cause pulmonary disease.3,4

In 1973, the Federal Food and Drug Administration concluded that trichloroethane may be responsible for side-effects from over-the-counter aerosols, and they asked that manufacturers of aerosols containing trichloroethane recall their products.5 Most patients who have ingested toxic doses of chloroform or trichloroethane have apparently not developed secondary pulmonary disease. The clinical course of a patient who developed pulmonary infiltrates and acute respiratory distress after injecting chloroform


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.